ICT&health May 11, 2021
Artur Olesch

Pharmaceutical companies were late to realize the impact of digitization on transforming the healthcare system and life sciences. Now they are trying to catch up by testing new business models and experimenting with innovations. Let’s analyze the digital-oriented strategic approach at Bayer, Johnson & Johnson, Servier, Astra Zeneca, Pfizer, and Novartis.

Bayer engages startups in search for innovations

Back in 2013, Bayer established its flagship accelerator for startups developing digital solutions oriented to the diseases for which the company offers drugs. Bayer G4A (previously Grants4Apps) was initially supposed to provide funding for startups working on mobile health applications. G4A has recently evolved into a global ecosystem of stakeholders working with startups and technology companies from the healthcare sector.

This approach...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Digital Health, Health IT, Pharma, Pharma / Biotech, Technology
AbbVie tries to reassure investors on Humira biosimilar threat
FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
This Biotech Startup Aims To Speed Up Drug Testing On Animals
Scientists reveal new method that could reduce waste from drug manufacturing
ETH develops AI algorithm for drug discovery based on 3D protein surface

Share This Article